Biohaven Ltd.
BHVN
NYSE
Healthcare
$15.96
+1.27%gain today
Market position
Market cap rank
#2220
of 2,614
1-day
+1.27%
1-month
+57.55%
6-month
+41.36%
YTD
+47.23%
1-year
+8.13%
5-year
—
Key figures
Market cap
$1.69B
P/E (live)
—
price ÷ annual EPS
P/E (reported)
-1.6
FY 2025
EPS
-$6.86
FY 2025
Dividend yield
0.00%
FY 2025
Dividend / share
$0.00
Gross margin
0.00%
FY 2025
Operating margin
0.00%
FY 2025
Net margin
0.00%
FY 2025
Return on equity
—
FY 2025
Valuation & financial health
Enterprise value
$1.27B
FY 2025
EV / EBITDA
-1.75
FY 2025
EV / Sales
0.00
FY 2025
Price / book
23.33
FY 2025
Price / sales
0.00
FY 2025
Earnings yield
-60.80%
FY 2025
FCF yield
-50.21%
FY 2025
Debt / equity
5.47
FY 2025
Current ratio
3.18
FY 2025
Return on assets
—
FY 2025
Return on invested capital
Financials · FY 2025
Revenue
$0
Gross profit
$-4.14M
Operating income
$-745.38M
EBITDA
$-727.46M
Net income
$-738.82M
Diluted EPS
-$6.86
Shares outstanding
107,624,885
Trading
Open
$15.89
Previous close
$15.76
Day range
$15.60 – $16.51
52-week range
$7.48 – $18.57
50-day avg
$11.21
200-day avg
$11.59
Volume
3,530,587
Avg volume
2,782,870
Beta
3.14
Price history
+8.13% over 1Y
Compare with peers
About Biohaven Ltd.
Biohaven Ltd. operates as a biopharmaceutical firm actively engaged in clinical trials. Its primary objective is to advance innovative treatments for disorders affecting the nervous and immune systems, with the potential to transform current medical interventions.
Visit websiteCompany info
CEO
Vladimir Coric
IPO date
Sep 23, 2022
Headquarters
New Haven, CT, US
Country
US
Fundamentals are annual. Figures labeled with their fiscal year.
